
Expres²ion will participate in key investor events in June 2021

Expres²ion Biotech Holding AB ("Expres²ion") will participate and hold presentations at key investor events in June, all of which will be held digitally. These include HC Andersen Capital's Life Science Seminar (June 16), and LifeSci Advisors Nordic Biotech Summit (June 29).

Meet and ask questions directly to our CEO, Bent U. Frandsen, at these investor events. To participate, please register via the links below.

HC Andersen Capital Life Science Seminar, June 16, 9:20 CET

More information (in Danish) and registration is available at the [event website](#).

LifeSci Advisors Nordic Biotech Summit, June 29, 16:00 CET (10:00 EST)

More information and registration is available at the [event website](#).

Certified Adviser

Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se

For further information about Expres²ion, please contact:

Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com

Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com

About Expres²ion

Expres²ion Biotechnologies ApS is a fully owned Danish subsidiary of Expres²ion Biotech Holding AB with company register number 559033-3729. Expres²ion has developed a unique technology platform, Expres², for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. Expres² is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, Expres²ion develops novel capsid VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com and www.adaptvac.com.